Stockscreener 앱 받기
1.43
11.73%
-0.19
시간 외 거래:
1.39
-0.04
-2.80%
Imunon Inc 주식(IMNN)의 최신 뉴스
Imunon Inc. appoints new CFO following termination - Investing.com Australia
Imunon Inc. appoints new CFO following termination By Investing.com - Investing.com South Africa
Imunon Appoints Kimberly Graper as Interim CFO - TipRanks
ImunonTerminates CFO David Gaiero's Service Agreement - marketscreener.com
Why Imunon, Inc. (IMNN) Surged Last Week - MSN
Imunon regains Nasdaq compliance with bid price By Investing.com - Investing.com South Africa
Imunon Regains Nasdaq Compliance with Bid Price - TipRanks
Imunon regains Nasdaq compliance with bid price - Investing.com
Imunon (NASDAQ:IMNN) Raised to Sell at Wall Street Zen - Defense World
Top Companies in the NASDAQ by Kalkine Leading Market Performers Today - Kalkine Media
Equities Analysts Offer Predictions for Imunon Q2 Earnings - Defense World
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th - GlobeNewswire
Phase 3 DNA Immunotherapy Developer IMUNON Opens Live Q&A with Investors Next Week - Stock Titan
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Yahoo Finance
IMUNON Announces Data Presented at ASCO Reinforces - GlobeNewswire
Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented - GuruFocus
IMNN: Promising Phase 2 Results in Ovarian Cancer Treatment | IMNN Stock News - GuruFocus
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study - Yahoo Finance
Imunon CEO says company ‘has never been stronger’ - TipRanks
IMNN Advances Cancer Treatment with Promising Phase 2 Results | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDA - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS - The Manila Times
Breakthrough Ovarian Cancer Drug Extends Patient Survival by 13 Months in Phase 2 Trial, ASCO Data Shows - Stock Titan
Should You Buy, Sell, or Hold Shopify Stock in June 2025? - The Globe and Mail
IMUNON launches up to $9.75M securities offering - MSN
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues By Investing.com - Investing.com Canada
Imunon (IMNN) Announces Plans to Offer 22.03 Million Shares | IM - GuruFocus
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues - Investing.com India
Imunon Faces Nasdaq Delisting Due to Non-Compliance - TipRanks
Public market insider selling at TerraVest Industries (TVK) - The Globe and Mail
Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance
IMUNON’s Stacy Lindborg on the long road to Phase III - The Pharma Letter
IMUNON Closes Up To $9.75 Million Private Placement Priced At-Th - GuruFocus
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Phase 3 Biotech IMUNON Raises $9.75M: Strategic Private Placement Fuels DNA Immunotherapy Development - Stock Titan
Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon By Stocktwits - Investing.com India
Imunon to present translational data in supporting Phase 2 OVATION Study - TipRanks
Imunon (IMNN) Gains Attention with Upcoming ESMO Presentation | - GuruFocus
IMUNON, Inc. to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 - marketscreener.com
IMNN's Immune Biomarker Data to be Highlighted at ESMO 2025 | IM - GuruFocus
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 - The Manila Times
Imunon announces up to $9.75M private placement priced at-the-market - Yahoo Finance
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025 | IMNN Stock News - GuruFocus
IMUNON Invited to Present Translational Data in Supporting - GlobeNewswire
Breakthrough Ovarian Cancer Drug Extends Life by 13 Months in Phase 2 Trial: Key Data Coming to ESMO - Stock Titan
Imunon Announces Private Placement Agreement with Investors - TipRanks
3 Penny Stocks to Watch Now, 5/27/25 - TipRanks
1.91%
1.17%
자본화:
|
볼륨(24시간):